<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Paul McGarry


Recent Posts

Champions Oncology Reports Quarterly Revenue of $5.1 Million

Mar 16, 2018 11:50:20 AM / by Paul McGarry

Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018

Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.

Read More →

Champions Oncology to Participate at the 30th Annual ROTH Conference

Feb 26, 2018 9:15:48 AM / by Paul McGarry

Hackensack, NJ – February 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings.

Read More →

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Feb 20, 2018 10:38:47 AM / by Paul McGarry

Patients with a rare tumor help drive a novel clinical study developed and launched by the Addario Lung Cancer Medical Institute with Champions Oncology

SAN CARLOS, Calif. and Hackensack, NJ (February 20, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.

Read More →